tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT), Becton Dickinson (BDX) and Humana (HUM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abbott Labs (ABTResearch Report), Becton Dickinson (BDXResearch Report) and Humana (HUMResearch Report).

Abbott Labs (ABT)

In a report released today, Cecilia Furlong from Morgan Stanley maintained a Buy rating on Abbott Labs, with a price target of $157.00. The company’s shares closed last Friday at $135.39, close to its 52-week high of $139.27.

According to TipRanks.com, Furlong is a 5-star analyst with an average return of 33.2% and a 63.0% success rate. Furlong covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Zimmer Biomet Holdings, and Irhythm Technologies.

Abbott Labs has an analyst consensus of Strong Buy, with a price target consensus of $144.00.

See the top stocks recommended by analysts >>

Becton Dickinson (BDX)

Morgan Stanley analyst Drew Ranieri maintained a Buy rating on Becton Dickinson today and set a price target of $300.00. The company’s shares closed last Friday at $253.28.

According to TipRanks.com, Ranieri is a 1-star analyst with an average return of -4.9% and a 38.1% success rate. Ranieri covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Becton Dickinson is a Hold with an average price target of $258.33.

Humana (HUM)

In a report released today, Ricky Goldwasser from Morgan Stanley maintained a Hold rating on Humana, with a price target of $410.00. The company’s shares closed last Friday at $355.15.

According to TipRanks.com, Goldwasser is a 5-star analyst with an average return of 14.9% and a 65.5% success rate. Goldwasser covers the Healthcare sector, focusing on stocks such as Lifestance Health Group, Bright Health Group, and Molina Healthcare.

Humana has an analyst consensus of Moderate Buy, with a price target consensus of $486.06, a 32.4% upside from current levels. In a report issued on January 5, Truist Financial also maintained a Hold rating on the stock with a $520.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ABT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed